Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi's 2-Pen Diabetes Combo Perplexes FDA

Executive Summary

Sanofi SA's strategy of using two pen injectors for its fixed-ratio combination that combines its experimental glucagon-like peptide-1 receptor agonist lixisenatide with its US-approved diabetes drug Lantus (basal insulin glargine) has the FDA perplexed and concerned about the potential for adverse events and medication errors.

Advertisement

Related Content

FDA On Novo's Diabetes Combo: It's Complicated
Sanofi Files LixiLan For Diabetes, Gambles Expensive Priority Review Voucher
Lantus Follow-On Basaglar OK'd, But Can Lilly Sell It?
Sanofi paying big for FDA voucher; Retrophin snags $245m

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel